These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 27115420)

  • 21. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
    Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
    Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional Crosstalk between CB and TRPV1 Receptors Protects Nigrostriatal Dopaminergic Neurons in the MPTP Model of Parkinson's Disease.
    Wi R; Chung YC; Jin BK
    J Immunol Res; 2020; 2020():5093493. PubMed ID: 33062722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parkin-knockout mice did not display increased vulnerability to intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Aguiar AS; Tristão FS; Amar M; Chevarin C; Lanfumey L; Mongeau R; Corti O; Prediger RD; Raisman-Vozari R
    Neurotox Res; 2013 Aug; 24(2):280-7. PubMed ID: 23588969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
    J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glutathione S-transferase pi mediates MPTP-induced c-Jun N-terminal kinase activation in the nigrostriatal pathway.
    Castro-Caldas M; Carvalho AN; Rodrigues E; Henderson C; Wolf CR; Gama MJ
    Mol Neurobiol; 2012 Jun; 45(3):466-77. PubMed ID: 22539231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathogenic Upregulation of Glial Lipocalin-2 in the Parkinsonian Dopaminergic System.
    Kim BW; Jeong KH; Kim JH; Jin M; Kim JH; Lee MG; Choi DK; Won SY; McLean C; Jeon MT; Lee HW; Kim SR; Suk K
    J Neurosci; 2016 May; 36(20):5608-22. PubMed ID: 27194339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of parkin in the differential susceptibility of tuberoinfundibular and nigrostriatal dopamine neurons to acute toxicant exposure.
    Benskey MJ; Manfredsson FP; Lookingland KJ; Goudreau JL
    Neurotoxicology; 2015 Jan; 46():1-11. PubMed ID: 25447324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of collapsin response mediator protein 4 suppresses dopaminergic neuron death in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
    Tonouchi A; Nagai J; Togashi K; Goshima Y; Ohshima T
    J Neurochem; 2016 Jun; 137(5):795-805. PubMed ID: 26991935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide.
    Morale MC; Serra PA; Delogu MR; Migheli R; Rocchitta G; Tirolo C; Caniglia S; Testa N; L'Episcopo F; Gennuso F; Scoto GM; Barden N; Miele E; Desole MS; Marchetti B
    FASEB J; 2004 Jan; 18(1):164-6. PubMed ID: 14630699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.
    Pattarini R; Smeyne RJ; Morgan JI
    Neuroscience; 2007 Mar; 145(2):654-68. PubMed ID: 17258864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minocycline enhances MPTP toxicity to dopaminergic neurons.
    Yang L; Sugama S; Chirichigno JW; Gregorio J; Lorenzl S; Shin DH; Browne SE; Shimizu Y; Joh TH; Beal MF; Albers DS
    J Neurosci Res; 2003 Oct; 74(2):278-85. PubMed ID: 14515357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: possible role of SOCS-1 in reducing pro-inflammatory responses.
    Lofrumento DD; Nicolardi G; Cianciulli A; De Nuccio F; La Pesa V; Carofiglio V; Dragone T; Calvello R; Panaro MA
    Innate Immun; 2014 Apr; 20(3):249-60. PubMed ID: 23764428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
    Wang S; Jing H; Yang H; Liu Z; Guo H; Chai L; Hu L
    J Ethnopharmacol; 2015 Apr; 164():247-55. PubMed ID: 25666429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action.
    Schober A; Peterziel H; von Bartheld CS; Simon H; Krieglstein K; Unsicker K
    Neurobiol Dis; 2007 Feb; 25(2):378-91. PubMed ID: 17141511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
    Rai SN; Yadav SK; Singh D; Singh SP
    J Chem Neuroanat; 2016 Jan; 71():41-9. PubMed ID: 26686287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation.
    Delgado M; Ganea D
    FASEB J; 2003 May; 17(8):944-6. PubMed ID: 12626429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
    Sconce MD; Churchill MJ; Greene RE; Meshul CK
    Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective role of 6-Hydroxy-1-H-Indazole in an MPTP-induced mouse model of Parkinson's disease.
    Xiao-Feng L; Wen-Ting Z; Yuan-Yuan X; Chong-Fa L; Lu Z; Jin-Jun R; Wen-Ya W
    Eur J Pharmacol; 2016 Nov; 791():348-354. PubMed ID: 27614126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.